An evergreen strategic venture capital fund of a large pharma closed at $100 million in 2013 and is managed by a small, dedicated team based in Massachusetts and California. The fund focuses on investments in companies developing pioneering bioelectronic medicines/neuromodulation devices and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The firm looks for investment opportunities globally.

The firm is a fund dedicated to advancing bioelectronic medicines and is looking to invest in high-return opportunities in three areas: (1) Teams pursuing new therapies for existing peripheral neurostimulation devices. (2) Teams developing novel bioelectronic medicine technologies for existing neurostimulation therapies. (3) Companies introducing advanced technologies that are enabling for bioelectronics medicines. The firm is particularly interested in improved neural interfaces, novel power sources and wireless powering technology, ultra-low power chip architectures, sensors that can close-the-loop for adaptive therapies and new implantation and imaging methods. The firm is stage agnostic.

The firm typically will take board of directors or board observer seat, but it is not necessary. The fund exclusively invests in privately-held companies and primarily in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital arm of a global supplier of building materials as well as a manufacturer of innovative material solutions is looking for companies that will align with the Saint-Gobain strategy for either equity investments, partnerships, licensing or acquisition. Within the life sciences, the firm will consider medical devices, novel materials, diagnostics, instruments and tools. The firm is willing to invest globally, and will invest as early as prototype/proof-of-concept stage.

Within the life sciences, the firm is interested in medical device, diagnostic or instrument and tool companies. The firm will consider all medical devices, but, if FDA approval is required, the firm prefers the company to be in the approval process. For diagnostics, the firm will consider both diagnostic/monitoring machines, tools, instruments & novel materials for Genomics & Cell & Gene therapies. The firm is also interested in instruments or tools that can be used in the medical field or for research purposes.

The firm can lead or co-invest in equity investing, and their involvement in the company after investment will depend on the partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A technology-based distributor and service solution provider of electronic components, enterprise IT and innovative solutions. Headquartered in Asia with a global offices, the firm’s main business domains lie in semiconductors, IoT and cybersecurity, but seeks to expand beyond these realms to create new businesses, including healthcare, life sciences. The firm has been making strategic investments periodically to make business partnership with external technology startups from all around the world that align with the firm’s interests. The firm’s investment is stage agnostic but mostly between Seed and Series B financing rounds. The firm is open to business partnership and global investment opportunities from any country.

Within life sciences and healthcare, the firm is open to opportunities in digital therapeutics, devices, and digital health. Within therapeutics, the firm is primarily seeking enabling technologies in chronic diseases as diabetes, sleep disorders, mental health, and also depression and dementia. The firm will generally not consider opportunities such as pre-clinical antibody or small molecule assets that require a long window. The firm is also interested in devices (open to both 510k and PMA) or digital health technologies that are in the fields of primary care, elderly care, and mental health. Some examples of the firm’s investments include a continuous glucose monitoring device, an AI-driven robotics platform for chronic care management, and a  digital therapeutics app for chronic diseases.

While the firm can invest in very early-stage companies, the firm prefers to invest in companies with a viable product that is ready to be tested in pilots or clinical trials at the earliest. The firm does not expect companies to have already received FDA approval and will help companies go through the regulatory process.

The firm has no specific company or management team requirements, and prefers to act as a co-investor. The firm does not require or seek board representation. As a completely strategic investor, the firm seeks to invest in companies that align with the firm’s new business goals and those that the firm can provide a strong value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm is based in the USA and focused in healthcare companies makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm is open to opportunities across North America and is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm is investing from its most recent fund, which closed in early 2020. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.